Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E7090 in FGFR2-fused Advanced Cholangiocarcinoma
NCT04238715Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jan 2020
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of tasurgratinib in cholangiocarcinoma (CCA), sponsored by Eisai Co., Ltd.. Started Jan 2020; status: completed.
02
Drugs
tasurgratinib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT04238715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04238715.